Labeeb Abboud

Labeeb Abboud has served in various leadership roles in global health product development and innovative financing, including the establishment of GHIC and the launch of its inaugural Global Health Investment Fund (GHIF). As Chairman since 2014, he has led GHIC’s engagement with government, philanthropic and private sector stakeholders and investors, oversight of GHIF’s investment management and operations, and third-party fund investments. In 2021, Labeeb joined GHIC as CEO as the organization expanded its mission to include global health security and launch its BARDA partnership and has led the evolution of organizational strategy and growth across key partnerships, investment management, and operational capabilities. Labeeb is a member of GHIC’s investment committee and serves as a board director or board observer for two of GHIC’s portfolio companies, Micron Biomedical and Univercells. Previously, he spent seventeen years in senior leadership roles at the International AIDS Vaccine Initiative (IAVI), where he was responsible for structuring a wide range of vaccine and antibody research, development, and licensing agreements in the fields of HIV, tuberculosis, COVID-19, and other emerging infectious diseases, with the goal of ensuring that products developed were made accessible and affordable globally. Prior to IAVI, his work experience spanned almost two decades in international law and financial services, including the structuring and launch of investment funds. He is a member of the Council on Foreign Relations and holds a B.A. from Wesleyan University and a J.D. from Georgetown University Law Center.